MGNX · NASDAQ
MacroGenics (MGNX) Stock Price & Fundamentals
MacroGenics (MGNX) closed at $487.25 on Oct 9, 2026, down 1.05% from the previous close of $492.40.
Share price, past year
1Y +28.09%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $487.25 |
| Sep 30, 2026 | $496.62 |
| Aug 31, 2026 | $475.93 |
| Jul 31, 2026 | $500.63 |
| Jun 30, 2026 | $464.73 |
| May 29, 2026 | $458.26 |
| Apr 30, 2026 | $450.79 |
| Mar 31, 2026 | $463.77 |
| Feb 27, 2026 | $459.40 |
| Jan 30, 2026 | $433.76 |
| Dec 31, 2025 | $451.16 |
| Nov 28, 2025 | $402.32 |
| Oct 31, 2025 | $386.89 |
Key statistics
- Market cap
- $31.01B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.23
- Revenue (TTM)
- $183.05M
- Net income (TTM)
- −$14.59M
- Shares outstanding
- 63.6M
- Dividend yield
- —
- 52-week range
- $373.54 – $507.69
MacroGenics's market cap is $31.01B, based on a share price of $487.25 and 63.6M shares outstanding as of Jun 30, 2026.
Financials
MacroGenics reported revenue of $149.50M for fiscal 2025, down 0.31% from fiscal 2024.
MacroGenics reported a net loss of $74.62M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $149.50M | −0.3% | −$74.62M | −49.9% | −$1.18 | −$82.95M |
| FY2024ended Dec 31, 2024 | $149.96M | +155.3% | −$66.97M | −44.7% | −$1.07 | −$72.08M |
| FY2023ended Dec 31, 2023 | $58.75M | −61.3% | −$9.06M | −15.4% | −$0.15 | −$79.97M |
| FY2022ended Dec 31, 2022 | $151.94M | +96.2% | −$119.76M | −78.8% | −$1.95 | −$90.58M |
| FY2021ended Dec 31, 2021 | $77.45M | −26.2% | −$202.12M | −261.0% | −$3.37 | −$150.03M |
| FY2020ended Dec 31, 2020 | $104.88M | +63.4% | −$129.74M | −123.7% | −$2.47 | −$117.80M |
| FY2019ended Dec 31, 2019 | $64.19M | +6.8% | −$151.81M | −236.5% | — | −$138.56M |
| FY2018ended Dec 31, 2018 | $60.12M | −61.9% | −$171.45M | −285.2% | — | −$178.19M |
| FY2017ended Dec 31, 2017 | $157.74M | +71.7% | −$19.63M | −12.4% | −$0.54 | −$15.00M |
| FY2016ended Dec 31, 2016 | $91.88M | — | −$58.53M | −63.7% | −$1.69 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $32.83M | $19.52M | $0.31 |
| Q1 FY2026ended Mar 31, 2026 | $20.78M | −$36.77M | −$0.58 |
| Q4 FY2025ended Dec 31, 2025 | $56.60M | −$14.16M | −$0.23 |
| Q3 FY2025ended Sep 30, 2025 | $72.84M | $16.82M | $0.27 |
| Q2 FY2025ended Jun 30, 2025 | $6.87M | −$36.25M | −$0.57 |
| Q1 FY2025ended Mar 31, 2025 | $13.19M | −$41.04M | −$0.65 |
| Q4 FY2024ended Dec 31, 2024 | $19.35M | −$15.42M | −$0.24 |
| Q3 FY2024ended Sep 30, 2024 | $110.71M | $56.31M | $0.90 |
Company profile
- Name
- MacroGenics, Inc.
- Ticker
- MGNX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 9704 Medical Center Drive, Rockville, MD 20850
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001125345
Recent SEC filings
- Aug 14, 2026
- Aug 13, 2026
- Jul 23, 2026
- Jul 8, 2026
- Jul 7, 2026
- May 20, 2026
- May 13, 2026
- May 13, 2026
Frequently asked questions
What is MacroGenics's stock price?
MacroGenics (MGNX) closed at $487.25 on Oct 9, 2026, down 1.05% from the previous close of $492.40.
What is MacroGenics's market cap?
MacroGenics's market cap is $31.01B, based on a share price of $487.25 and 63.6M shares outstanding as of Jun 30, 2026.
How much revenue does MacroGenics make?
MacroGenics reported revenue of $149.50M for fiscal 2025, down 0.31% from fiscal 2024.
Does MacroGenics pay a dividend?
MacroGenics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from MacroGenics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures